Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit

Wojciech Krajewski, Marco Moschini, Łukasz Nowak, Sławomir Poletajew, Andrzej Tukiendorf, Luca Afferi, Jeremy Yuen‐Chun Teoh, Tim Muilwijk, Steven Joniau, Alessandro Tafuri, Alessandro Antonelli, Alessandra Gozzo, Andrea Mari, Ettore Di Trapani, Kees Hendricksen, Mario Álvarez‐Maestro, Andrea Rodriguez Serrano, Giuseppe Simone, Stefania Zamboni, Claudio Simeone, Maria Cristina Marconi, Riccardo Mastroianni, Guillaume Ploussard, Paweł Rajwa, Ekaterina Laukhtina, Aleksandra Zdrojowy-Wełna, Anna Kołodziej, Andrzej Paradysz, Karl H. Tully, Joanna Krajewska, Radosław Piszczek, Évanguelos Xylinas, Romuald ZdrojowyJournal of Clinical Medicine 2020 · DOI

TL;DR

This study investigated whether performing a second transurethral resection (reTURB) after Bacillus Calmette-Guérin (BCG) immunotherapy, compared to before, impacts oncological outcomes in patients with high-grade T1 bladder cancer. The findings suggest that the timing of reTURB relative to BCG induction does not significantly alter recurrence-free or progression-free survival rates.

What Problem Does This Paper Address?

The standard treatment for high-risk, non-muscle-invasive bladder cancer (NMIBC) involves transurethral resection of bladder tumors (TURB) followed by Bacillus Calmette-Guérin (BCG) immunotherapy. A critical step in managing these cancers is ensuring complete tumor removal and accurate staging, as residual disease or understaging can lead to worse outcomes. Current European Association of Urology (EAU) guidelines recommend a restaging TURB (reTURB) 2-6 weeks after the initial TURB, typically before BCG induction. However, in clinical practice, logistical issues or patient factors sometimes lead to reTURB being performed after the BCG induction course. There was a lack of comparative data on whether this post-BCG reTURB impacts oncological outcomes compared to the standard pre-BCG approach. This study aimed to fill that gap by comparing these two sequences.

Methods

This was a retrospective, multicenter cohort study involving 645 patients with primary T1 high-grade (HG) NMIBC treated between 2001 and 2019 across 12 tertiary care centers. Patients were divided into two groups: those who underwent reTURB before BCG induction (Pre-BCG group) and those who underwent reTURB after BCG induction (Post-BCG group).

To account for potential differences in patient characteristics between the groups, the researchers employed two statistical methods:

  • Propensity-Score Matching (PSM): This technique creates matched pairs of patients from each group who have similar baseline characteristics (e.g., age, gender, smoking history, tumor size, presence of muscularis propria). This helps to isolate the effect of the reTURB timing.
  • Inverse Probability of Treatment Weighting (IPW): This method assigns weights to patients to create a pseudo-population where the treatment groups are balanced on observed covariates, effectively mimicking a randomized trial.

The primary outcomes assessed were recurrence-free survival (RFS) and progression-free survival (PFS) over a five-year period and the entire observation period.

Datasets

The study utilized data from 645 patients with primary T1HG NMIBC from 12 tertiary care centers. This dataset was collected retrospectively from patient records. No new datasets or benchmarks were introduced.

Key Insights and Ideas

  • BCG's Potential Role in Residual Disease: The study observed a statistically significant lower rate of residual disease in the Post-BCG group (30%) compared to the Pre-BCG group (38%). This suggests that BCG immunotherapy itself might have a beneficial effect in reducing or eliminating residual tumor cells, even before a second resection.
  • Residual Tumors are a Major Risk Factor: Regardless of reTURB timing, the presence of residual tumors at reTURB was strongly associated with an increased risk of cancer recurrence and progression (2.6- and 3-fold higher, respectively). This reinforces the importance of complete tumor resection.
  • Timing May Not Matter for Survival: The core finding is that the timing of reTURB relative to BCG induction does not appear to significantly impact long-term oncological outcomes (RFS and PFS). This challenges the strict adherence to pre-BCG reTURB if logistical issues arise.

Key Results

  • No Significant Difference in Survival: After both PSM and IPW analyses, there were no statistically significant differences in five-year RFS or PFS between the Pre-BCG and Post-BCG groups.
  • Five-year RFS: 64.7% (Pre-BCG) vs. 69.1% (Post-BCG) (p > 0.05)
    • Five-year PFS: 82.7% (Pre-BCG) vs. 83.3% (Post-BCG) (p > 0.05)
  • IPW showed Borderline Significance: While not reaching statistical significance in all analyses, IPW showed a trend towards better five-year RFS for the Post-BCG group (68.9% vs. 61.2%, p = 0.063). This suggests a potential, albeit weak, benefit that warrants further investigation.
  • Lower Residual Disease in Post-BCG Group: The rate of residual disease detected at reTURB was lower in the Post-BCG group (30%) compared to the Pre-BCG group (38%, p = 0.029).

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: Data was collected retrospectively, which can introduce biases.
  • Lack of Randomization: The allocation to Pre-BCG vs. Post-BCG reTURB was based on surgeon discretion and local protocols, not randomization.
  • Exclusion of T2 Lesions: Patients with T2 lesions identified at reTURB were excluded as they would not receive BCG therapy, potentially limiting the generalizability of findings for this subgroup.
  • Incomplete Data: Details on BCG strain, surgeon experience, and technical aspects of the procedure were not uniformly available or reliable.
  • No Central Pathology Review: Specimens were evaluated at participating centers, not centrally.
  • Limited CSS Analysis: Cancer-specific death (CSS) events were too few for robust statistical analysis.

Future work could involve prospective, randomized controlled trials to definitively confirm these findings. Further research could also explore the impact of BCG strain and dose on residual disease and outcomes, as well as investigate the optimal timing for reTURB in specific patient subgroups. The potential benefit of BCG in reducing residual disease warrants further investigation.

Summary updated

Abstract

Our results suggest that there might be no difference in recurrence-free survival and progression-free survival rates, regardless of whether patients have reTURB performed before or after BCG induction.
BibTeX
@article{krajewski2020restaging,
  author = {Wojciech Krajewski and Marco Moschini and Łukasz Nowak and Sławomir Poletajew and Andrzej Tukiendorf and Luca Afferi and Jeremy Yuen‐Chun Teoh and Tim Muilwijk and Steven Joniau and Alessandro Tafuri and Alessandro Antonelli and Alessandra Gozzo and Andrea Mari and Ettore Di Trapani and Kees Hendricksen and Mario Álvarez‐Maestro and Andrea Rodriguez Serrano and Giuseppe Simone and Stefania Zamboni and Claudio Simeone and Maria Cristina Marconi and Riccardo Mastroianni and Guillaume Ploussard and Paweł Rajwa and Ekaterina Laukhtina and Aleksandra Zdrojowy-Wełna and Anna Kołodziej and Andrzej Paradysz and Karl H. Tully and Joanna Krajewska and Radosław Piszczek and Évanguelos Xylinas and Romuald Zdrojowy},
  title = {{Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit}},
  journal = {Journal of Clinical Medicine},
  year = {2020},
  doi = {10.3390/jcm9103306},
}
Figure